Header links
Intranet
Donate now
image/svg+xml Map
Contact us

Ensayo en fase III, multicéntrico, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia y seguridad del sibeprenlimab administrado por vía subcutánea en sujetos con nefropatía por inmunoglobulina AEnsayo del sibeprenlimab en el tratamiento de la nefropatía por inmunoglobulina A

Contact
  • Protocol code: MB-106 (417-201-00007)
  • EudraCT code: No aplica
  • Pathology: Símptomes, signes i troballes anormals clíniques i de laboratori, no classificades enlloc més
  • Principal investigator:  Soler Romeo, Maria Jose
  • Research group:  Nefrologia i trasplantament renal
  • Service: Nefrologia
  • Phase: Fase III
  • Recruiting: Open
  • Status: Iniciat

Contact Form

I have read and accept the data protection policy *.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.
Purpose: Request for information on VHIR clinical research.
Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.
Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.
Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.
Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information 
The request for information on a research project or clinical trial does not entail inclusion in it.

Pauta de dosificación ajustable de brodalumab en comparación con el tratamiento estándar con brodalumab durante 52 semanas en pacientes con psoriasis en placas de moderada a grave y 120 kg de peso corporal

Contact
  • Protocol code: LP0160-1329
  • EudraCT code: 2017-004998-13
  • Pathology: Malalties de la pell i del teixit subcutani
  • Principal investigator:  Aparicio Español, Gloria
  • Service: Dermatologia
  • Phase: Fase IV
  • Recruiting: Open
  • Status: Tancat

Contact Form

I have read and accept the data protection policy *.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.
Purpose: Request for information on VHIR clinical research.
Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.
Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.
Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.
Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information 
The request for information on a research project or clinical trial does not entail inclusion in it.

Protocolo maestro para ensayos clínicos dirigido a macrotrombosis, microinmunotrombosis, hiperinflamación vascular e hipercoagulabilidad y el sistema renina-angiotensina-aldosterona (SRAA) en pacientes hospitalizados con COVID-19

Contact
  • Protocol code: ACTIV-4
  • EudraCT code: 2022-000715-31
  • Pathology: Certes malalties infeccioses i parasitàries
  • Principal investigator:  Burgos Cibrian, Joaquin
  • Research group:  Malalties infeccioses
  • Service: Infeccioses
  • Phase: Fase III
  • Recruiting: Open
  • Status: Iniciat

Contact Form

I have read and accept the data protection policy *.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.
Purpose: Request for information on VHIR clinical research.
Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.
Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.
Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.
Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information 
The request for information on a research project or clinical trial does not entail inclusion in it.

BHV3000-407: Estudio en fase IV, aleatorizado, doble ciego, controlado con placebo, para evaluar la eficacia y tolerabilidad de rimegepant para la prevención de la migraña en adultos con antecedentes de respuesta inadecuada a medicamentos preventivos orales.

Contact
  • Protocol code: BHV3000-407
  • EudraCT code: 2022-001176-34
  • Pathology: Malalties del sistema nerviós
  • Principal investigator:  Pozo Rosich, Patricia
  • Research group:  Cefalea i dolor neurològic
  • Service: Neurologia
  • Phase: Fase IV
  • Recruiting: Open
  • Status: Iniciat

Contact Form

I have read and accept the data protection policy *.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.
Purpose: Request for information on VHIR clinical research.
Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.
Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.
Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.
Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information 
The request for information on a research project or clinical trial does not entail inclusion in it.

Estudio de extensión multicéntrico, abierto y doble ciego, controlado con placebocon retirada aleatorizada, seguido de ciclos de tratamiento abierto de larga duraciónpara evaluar la eficacia, seguridad y tolerabilidad de remibrutinib (LOU064) enpacientes adultos con urticaria crónica espontánea que hayan completado losestudios anteriores de fase III de remibrutinib.

Contact
  • Protocol code: CLOU064A2303B
  • EudraCT code: 2022-001034-11
  • Pathology: Malalties de la pell i del teixit subcutani
  • Principal investigator:  Labrador Horrillo, Moisés
  • Research group:  Malalties sistèmiques
  • Service: Medicina Interna
  • Phase: Fase III
  • Recruiting: Open
  • Status: Iniciat

Contact Form

I have read and accept the data protection policy *.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.
Purpose: Request for information on VHIR clinical research.
Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.
Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.
Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.
Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information 
The request for information on a research project or clinical trial does not entail inclusion in it.

Estudio de fase IIb, multicéntrico, aleatorizado, doble ciego y controlado con placebo para determinar la eficacia y la seguridad de BIIB122 en participantes con enfermedad de Parkinson

Contact
  • Protocol code: 283PD201
  • EudraCT code: 2021-004849-20
  • Pathology: Malalties del sistema nerviós
  • Principal investigator:  Hernández Vara, Jorge
  • Research group:  Malalties neurodegeneratives
  • Service: Neurologia
  • Phase: Fase II
  • Recruiting: Open
  • Status: Iniciat

Contact Form

I have read and accept the data protection policy *.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.
Purpose: Request for information on VHIR clinical research.
Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.
Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.
Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.
Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information 
The request for information on a research project or clinical trial does not entail inclusion in it.

Estudio de fase 2, aleatorizado, sin enmascaramiento, en el que se evalúa abemaciclib en combinación con irinotecán y temozolomida en participantes con sarcoma de Ewing recidivante o resistente al tratamiento

Contact

Contact Form

I have read and accept the data protection policy *.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.
Purpose: Request for information on VHIR clinical research.
Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.
Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.
Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.
Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information 
The request for information on a research project or clinical trial does not entail inclusion in it.

Estudio de Fase II, multicéntrico, aleatorizado, doble ciego, controlado con placebo y de grupos paralelos para evaluar la eficacia y la seguridad de CC 99677 en sujetos con espondilitis anquilosante activa

Contact
  • Protocol code: CC-99677-AS-001
  • EudraCT code: 2019-004108-37
  • Pathology: Malalties del sistema osteomuscular i del teixit connectiu
  • Principal investigator:  Marsal Barril, Sara
  • Research group:  Reumatologia
  • Service: Reumatologia
  • Phase: Fase II
  • Recruiting: Closed
  • Status: Iniciat

Contact Form

I have read and accept the data protection policy *.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.
Purpose: Request for information on VHIR clinical research.
Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.
Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.
Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.
Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information 
The request for information on a research project or clinical trial does not entail inclusion in it.

Estudio aleatorizado, doble ciego con doble enmascaramiento y grupos paralelos en el que se compara la eficacia y seguridad de remibrutinib 100 mg b.i.d. frente a teriflunomida 14 mg q.d. en participantes con esclerosis múltiple recurrente, seguido de una extensión abierta del tratamiento con remibrutinib.

Contact
  • Protocol code: CLOU064C12301
  • EudraCT code: 2020-005899-36
  • Pathology: Malalties del sistema nerviós
  • Principal investigator:  Montalban Gairín, Xavier
  • Research group:  Neuroimmunologia clínica
  • Service: Neuroimmunologia
  • Phase: Fase III
  • Recruiting: Open
  • Status: Iniciat

Contact Form

I have read and accept the data protection policy *.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.
Purpose: Request for information on VHIR clinical research.
Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.
Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.
Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.
Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information 
The request for information on a research project or clinical trial does not entail inclusion in it.

Estudio de fase III, abierto, de un solo grupo y con dosis repetidas, para evaluar la seguridad y tolerabilidad, la farmacocinética y la actividad antiviral de maribavir para el tratamiento de la infección por el citomegalovirus (CMV) en niños y adolescentes que han recibido un trasplante de células madre hematopoyéticas (HSCT) o un trasplante de órgano sólido (TOS)

Contact

Contact Form

I have read and accept the data protection policy *.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.
Purpose: Request for information on VHIR clinical research.
Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.
Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.
Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.
Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information 
The request for information on a research project or clinical trial does not entail inclusion in it.
Subscribe to